. Author manuscript; available in PMC: 2017 Dec 21.

Published in final edited form as: J Viral Hepat. 2016 Dec 1;24(5):380–388. doi: 10.1111/jvh.12656

TABLE 3.

Association between anti-HCV/HCV RNA status and all-cause mortality among 9117 NHANES III participants aged 18–59 years

	Anti-HCV negative N=8866	Anti-HCV positive (RNA positive and negative) N=251		Anti-HCV and HCV RNA positive (chronic HCV) N=203

		MRR (95% CI)^a	P-value	MRR (95% CI)^a	P-value
All-cause mortality, no.	861	69		60

Age and sex adjusted	1.00 [Reference]	3.76 (2.43–5.83)	<.001	4.59 (2.96–7.11)	<.001

Partially adjusted^b	1.00 [Reference]	2.45 (1.51–3.98)	.0003	2.95 (1.86–4.69)	<.001

Fully adjusted^c	1.00 [Reference]	2.20 (1.32–3.66)	.002	2.63 (1.59–4.37)	<.001

Mortality rate ratio (95% confidence interval) versus anti-HCV negative.

Partial adjustment: demographics (age, sex, race/ethnicity, marital status, education, poverty income ratio), lifestyle (alcohol consumption, smoking status, lifetime cocaine and marijuana use, lifetime number of sexual partners), body mass index and comorbidities/viruses (cancer, diabetes, hepatitis A antibody, hepatitis E antibody).

Full adjustment factors: partial adjustment factors, liver function biomarkers (ALT, total bilirubin).